Radiation plus immunotherapy for recurrent rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies a combination of SBRT (a precise kind of radiation) and an immunotherapy drug (PD-1 antibody) for people whose rectal cancer has come back in the pelvis and cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or stop it from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your rectal cancer has returned in the pelvis and doctors say it cannot be fully removed with surgery.
- You are between 18 and 75 years old.
- Your tumor type is called pMMR or MSS (a lab test shows this).
- You have not had radiation before, or if you did, it was at least 6 months ago and the dose was below 50.4 Gy.
- You are in good overall health (ECOG 0 or 1) and your blood counts, liver, and kidney function are within certain limits.
- You have no other active cancer, no serious heart or lung problems, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests targeted radiation (SBRT) for people whose rectal cancer has come back in the pelvis and cannot be surgically removed. The goal is to see if this focused radiation can control the tumor with fewer side effects.
This study tests a combination of radiation, chemotherapy, and an immunotherapy drug (toripalimab) before surgery for patients whose rectal cancer has returned locally. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
Hear when a new Unresectable Locally Recurrent Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.